Noe LGA Gesundheit Thermenregion GmbH
- Address
- Corvinusring 3-5, 2700 Wiener Neustadt, Austria
Noe LGA Gesundheit Thermenregion GmbH - Comprehensive Oncology Research Center
Noe LGA Gesundheit Thermenregion GmbH is a distinguished clinical research institution specializing in advanced oncology trials across multiple cancer types. The center demonstrates particular expertise in evaluating novel targeted therapies, immunotherapies, and combination treatment strategies for patients with solid tumors and hematologic malignancies. With extensive involvement in international phase II and III clinical trials, the facility plays a crucial role in advancing precision medicine approaches for cancer treatment.
- Breast Cancer: Investigating hormone receptor-positive and HER2-targeted therapies, including CDK4/6 inhibitors, antibody-drug conjugates, and endocrine therapy combinations in early and metastatic settings
- Gastrointestinal Malignancies: Leading research in gastric, gastroesophageal junction, colorectal, biliary tract, and pancreatic cancers with focus on HER2-directed therapies, KRAS inhibitors, and FGFR-targeted treatments
- Cancer-Associated Thromboembolism: Specialized trials evaluating novel anticoagulation strategies for venous thromboembolism management in oncology patients
- Hematologic Disorders: Clinical investigations in multiple myeloma, follicular lymphoma, and polycythemia vera utilizing immunomodulatory agents and targeted therapies
The center's research portfolio encompasses cutting-edge therapeutic modalities including antibody-drug conjugates, immune checkpoint inhibitors, and molecularly targeted agents directed against specific genetic alterations. Beyond oncology, the institution also contributes to cardiovascular research with biomarker-driven risk management studies. This comprehensive approach positions Noe LGA Gesundheit Thermenregion GmbH as a key contributor to translational research bridging laboratory discoveries and clinical practice improvements for patients with life-threatening diseases.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 8 therapeutic areas and 15 of 85 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 85 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 14 by active trials.
- 1AstraZeneca AB2active
lock +13 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB4trials
lock +3 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 152 other sites in Austria
Therapeutic Area Benchmark — Austria
Select a therapeutic area to compare against other sites in Austria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Austria
Market Share
Country: Austria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Noe LGA Gesundheit Thermenregion GmbH
lock Showing 1 of 27 trials — the rest is available on a paid plan.
IMP list
lock Showing 1 of 85 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Fluorouracil | 8 | Unknown | 2016-11-07 | 2025-07-30 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.